# NESP Pediatric Study

> **NCT00527137** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 120 (estimated)

## Conditions studied

- Pre-dialysis
- End Stage Renal Disease

## Interventions

- **DRUG:** darbepoetin alfa
- **DRUG:** rHuEPO

## Key facts

- **NCT ID:** NCT00527137
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2004-11
- **Final completion:** 2004-11
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2013-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00527137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00527137, "NESP Pediatric Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00527137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*